FENC - Fennec Pharmaceuticals Inc. Narxning prognoz qilingan daromadga nisbati

Fennec (FENC) - korporativ logo

Fennec Pharmaceuticals (FENC) biznesi bolalar onkologiyasining ustunligi bilan himoyalangan, biroq u kritik darajada yagona mahsulotga tayanadi. Oldingi sotuvlar nisbatidagi narx baholash usuli ushbu xatarlarni muvozanatga keltirishga yordam beradi va bunda parametr 0.30 qiymatiga yetadi. Samara keltiruvchi miqyosga esa ishlab chiqarishni autsorsing qilish va mavjud klinika tarmoqlaridan foydalanish orqali erishiladi, bu esa kompaniyaga sezilarli kapital xarajatlarsiz foydani oshirish imkonini beradi.

Fennec Pharma - FENC Prognoz narxning daromadga nisbati (davr: 09.04.2023 - 13.11.2026)

Fennec (FENC) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi statistikasi:
Kompaniyaning umumiy tahlili:Fennec Pharmaceuticals Inc. FENC
fennecpharma.com tomonidan chiqariladigan mahsulotlar

Forward P/S biznesning bozor qiymatini kutilayotgan savdo hajmi bilan nisbatda baholaydi, bu esa investorga haqiqiy daromad o'zgarishlari yuz berishidan oldin aktivlarning haddan tashqari qimmat baholanganini aniqlash imkonini beradi. Fennec Pharmaceuticals (FENC) uchun forward narx-savdo ko'rsatkichi pediatrik onkologiya bozorining torligi va sug'urta to'lovlari bilan bog'liq xatarlar tufayli juda muhimdir; shuning uchun grafikdagi keskin og'ishlar asossiz bozor kutuvlari yoki potentsial talabning fundamental qisqarishi haqida signal beradi.

Muhim raqobatchilar

Narxning prognoz qilingan daromadga nisbati Incyte INCY|Hutchison MediPharma - Narxning prognoz qilingan daromadga nisbati|NUVB - Narxning prognoz qilingan daromadga nisbati|Bozor kapitallashuvining kelajakdagi daromadga nisbati Day One Biopharmaceuticals Inc|MNPR: Forvard P/S multiplikatori|Prognoz narxning daromadga nisbati inhibrx.com INBX|Forvard narx/daromad multiplikatori IMAB|Bozor kapitallashuvining kelajakdagi daromadga nisbati Heron Therapeutics Inc HRTX|Forvard narx/daromad multiplikatori NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Sotuvga nisbatan forvard narx|Corbus Pharmaceuticals - Forvard narx/daromad multiplikatori|Narxning kutilayotgan daromadga nisbati CRDF (Cardiff Oncology Inc.)|BeyondSpring - Forvard P/S multiplikatori|Sotuvga nisbatan forvard narx BCAB (BioAtla, Inc.)|LIXT: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Citius Pharmaceuticals, Inc. (CTXR)|Narxning prognoz qilingan daromadga nisbati Cellectar Biosciences|BLRX: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori CANF|Forvard P/S multiplikatori aprea.com (APRE)|Narxning prognoz qilingan daromadga nisbati Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Kelajakdagi narxning daromadga nisbati|NCNA: Forvard narx/daromad multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati chimerix.com|CYCC: Forvard P/S multiplikatori|Kelajakdagi narxning daromadga nisbati GTHX (G1 Therapeutics)|KRON (Kronos Bio Corp) - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Kintara Pharma KTRA|Narxning prognoz qilingan daromadga nisbati Oncternal Therapeutics (ONCT)|portagebiotech.com - Kapitalizatsiyaning prognoz qilingan daromadga nisbati